Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
- 357 Downloads
Goals of work
Prevention of chemotherapy-induced nausea and vomiting (CINV) with standard antiemetics has been more difficult to achieve in female patients. Data from two phase III trials of the NK1 antagonist aprepitant were assessed for potential effect of gender on treatment response.
Patients and methods
1,044 patients receiving cisplatin (≥70 mg/m2) were randomly assigned to control regimen [ondansetron (O) 32 mg i.v. and dexamethasone (D) 20 mg p.o. on day 1; D 8 mg twice daily on days 2–4] or aprepitant (A) regimen (A 125 mg p.o. plus O 32 mg and D 12 mg on day 1; A 80 mg and D 8 mg once daily on days 2–3; and D 8 mg on day 4). The primary endpoint was overall complete response (no emesis and no rescue therapy over days 1–5). Data were analyzed by a modified intent-to-treat approach. Between-treatment comparisons for each gender were made using logistic regression.
Women comprised 42 and 43% of the aprepitant and control groups, respectively. In the control group, 41% of women had overall complete response compared with 53% of men. In the aprepitant group, 66% of women had overall complete response compared with 69% of men.
The addition of aprepitant may negate the adverse prognostic effect of female gender on the prevention of CINV in patients receiving highly emetogenic chemotherapy.
KeywordsNausea and vomiting Aprepitant NK1 antagonist Cancer Supportive care
This study was funded by Merck and Co., Inc., manufacturer of aprepitant.
- 6.de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M et al (2004) The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 40(3):403–410PubMedGoogle Scholar
- 8.DeletedGoogle Scholar
- 9.Flores CA, Shughrue P, Petersen SL, Mokha SS (2003) Sex-related differences in the distribution of opioid receptor-like 1 receptor mRNA and colocalization with estrogen receptor mRNA in neurons of the spinal trigeminal nucleus caudalis in the rat. Neuroscience 118(3):769–778PubMedCrossRefGoogle Scholar
- 12.Hesketh PJ, Grunberg SM, Gralla RJ, Warr D, Roila F, de Wit R et al (2003) The oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol 21(22):4112–4119PubMedCrossRefGoogle Scholar
- 16.Package Circular (2003) EMEND (aprepitant) Capsules. PDR Electronic Library. Ref Type: Electronic CitationGoogle Scholar
- 17.Poli-Bigelli S, Rodriguez-Pereira J, Guoguang-Ma J, Carides AD, Eldridge K, Evans JK et al (2003) Addition of the NK1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo controlled trial in Latin America. Cancer 97(12):3090–3098PubMedCrossRefGoogle Scholar
- 22.Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P et al (1992) Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer 66(1):192–197PubMedGoogle Scholar